Overall survival of patients diagnosed with accelerated/blast-phase myeloproliferative neoplasms from 2017 onward. (A) OS of patients diagnosed with MPN-AP/BP from 2017 onward. (B) OS of patients with MPN-AP/BP by frontline treatment approach.